Secarna Pharmaceuticals and Vect-Horus have entered a research collaboration for developing RNA-targeted therapeutics capable of crossing the blood-brain barrier (BBB) for treating central nervous system (CNS) diseases.
The European Commission (EC) has granted orphan drug designation (ODD) to Medipal and JCR Pharmaceuticals' investigational drug, JR-446, to treat mucopolysaccharidosis type IIIB (MPS IIIB), also known as Sanfilippo syndrome type B.
GRIN Therapeutics has announced a collaboration with Angelini Pharma to develop and commercialise radiprodil outside of North America.
The University of Calgary and Alberta Children’s Hospital have secured C$68,000 ($48,694) from Brain Cancer Canada for a research initiative spearhead by Dr Patrick Sipila and Dr Aru Narendran, aimed at improving outcomes for children with aggressive brain cancers.
BrainChild Bio's B7 homolog 3 (B7-H3) targeting autologous chimeric antigen receptor (CAR) T-cell therapy, BCB-276, has received the regenerative medicine advanced therapy (RMAT) designation from the US Food and Drug Administration (FDA) for treating diffuse intrinsic pontine glioma (DIPG).
US-based firm MIRA Pharmaceuticals has secured approval from its board of directors to acquire SKNY Pharmaceuticals, a company engaged in the development of SKNY-1 oral drug candidate for weight loss and smoking cessation.
Viatris has submitted applications to Japan's Ministry of Health, Labor and Welfare (MHLW) for the approval of Effexor SR Capsules (venlafaxine hydrochloride) to treat adults with generalised anxiety disorder (GAD).
Biogen has received fast track designation from the US Food and Drug Administration (FDA) for its investigational antisense oligonucleotide (ASO) therapy, BIIB080, to treat Alzheimer's disease.
As a part of a broader investment round, Beyond Air’s subsidiary NeuroNOS has received an initial equity financing of $2m from private investors, aimed at expediting the preclinical development of its small-molecule drug for paediatrics with autism.
Atalanta Therapeutics has secured oversubscribed $97m in Series B financing to propel the Phase I trials of its RNA interference (RNAi) treatments targeting KCNT1-related epilepsy as well as Huntington’s disease.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.